Multidrug-Resistant Tuberculosis
Cross-source consensus on Multidrug-Resistant Tuberculosis from 1 sources and 6 claims.
1 sources · 6 claims
How it works
Interactions
Other
Highlighted claims
- MDR-TB is defined as tuberculosis resistant to both isoniazid and rifampicin. — Population-based study of pharmacogenetics and pharmacokinetics in Southern African patients with multidrug-resistant tuberculosis (PoPG): a protocol for the Namibian cohort
- Tuberculosis remains the leading cause of death from a single infectious agent globally. — Population-based study of pharmacogenetics and pharmacokinetics in Southern African patients with multidrug-resistant tuberculosis (PoPG): a protocol for the Namibian cohort
- In 2023, approximately 8.2 million people were diagnosed with TB worldwide and 1.25 million died from the disease. — Population-based study of pharmacogenetics and pharmacokinetics in Southern African patients with multidrug-resistant tuberculosis (PoPG): a protocol for the Namibian cohort
- Namibia, South Africa, Zambia and Uganda are described as being at the centre of a dual TB and HIV coepidemic. — Population-based study of pharmacogenetics and pharmacokinetics in Southern African patients with multidrug-resistant tuberculosis (PoPG): a protocol for the Namibian cohort
- HIV coinfection and antiretroviral therapy may influence TB drug exposure and drug-drug interactions in MDR-TB patients. — Population-based study of pharmacogenetics and pharmacokinetics in Southern African patients with multidrug-resistant tuberculosis (PoPG): a protocol for the Namibian cohort
- In Namibia, MDR-TB accounts for an estimated 4.5% of new TB cases and 7.9% of previously treated cases. — Population-based study of pharmacogenetics and pharmacokinetics in Southern African patients with multidrug-resistant tuberculosis (PoPG): a protocol for the Namibian cohort